Search

Your search keyword '"Rossi, Davide"' showing total 42 results

Search Constraints

Start Over You searched for: Author "Rossi, Davide" Remove constraint Author: "Rossi, Davide" Publication Year Range This year Remove constraint Publication Year Range: This year
42 results on '"Rossi, Davide"'

Search Results

1. Culsans: An Efficient Snoop-based Coherency Unit for the CVA6 Open Source RISC-V application processor

2. Spatzformer: An Efficient Reconfigurable Dual-Core RISC-V V Cluster for Mixed Scalar-Vector Workloads

3. Occamy: A 432-Core 28.1 DP-GFLOP/s/W 83% FPU Utilization Dual-Chiplet, Dual-HBM2E RISC-V-based Accelerator for Stencil and Sparse Linear Algebra Computations with 8-to-64-bit Floating-Point Support in 12nm FinFET

4. Unleashing OpenTitan's Potential: a Silicon-Ready Embedded Secure Element for Root of Trust and Cryptographic Offloading

5. A Gigabit, DMA-enhanced Open-Source Ethernet Controller for Mixed-Criticality Systems

6. Assessing the Performance of OpenTitan as Cryptographic Accelerator in Secure Open-Hardware System-on-Chips

7. TOP: Towards Open & Predictable Heterogeneous SoCs

8. A Heterogeneous RISC-V based SoC for Secure Nano-UAV Navigation

9. TitanCFI: Toward Enforcing Control-Flow Integrity in the Root-of-Trust

11. Early reappearance of intraclonal proliferative subpopulations in ibrutinib-resistant chronic lymphocytic leukemia

16. Distinct Hodgkin lymphoma subtypes defined by noninvasive genomic profiling

18. First-line venetoclax combinations versus chemoimmunotherapy in fit patients with chronic lymphocytic leukaemia (GAIA/CLL13): 4-year follow-up from a multicentre, open-label, randomised, phase 3 trial

19. Activity of venetoclax in patients with relapsed or refractory chronic lymphocytic leukaemia: analysis of the VENICE-1 multicentre, open-label, single-arm, phase 3b trial

20. Targeting CD19-positive lymphomas with the antibody-drug conjugate loncastuximab tesirine: preclinical evidence as single agent and in combination therapy

23. Table S3 from ERBB4-Mediated Signaling Is a Mediator of Resistance to PI3K and BTK Inhibitors in B-cell Lymphoid Neoplasms

24. Figure S5 from ERBB4-Mediated Signaling Is a Mediator of Resistance to PI3K and BTK Inhibitors in B-cell Lymphoid Neoplasms

25. Supplementary Table 7 from ERBB4-Mediated Signaling Is a Mediator of Resistance to PI3K and BTK Inhibitors in B-cell Lymphoid Neoplasms

26. Figure S19 and references for supplementary figures from ERBB4-Mediated Signaling Is a Mediator of Resistance to PI3K and BTK Inhibitors in B-cell Lymphoid Neoplasms

27. Supplementary Table 5 from ERBB4-Mediated Signaling Is a Mediator of Resistance to PI3K and BTK Inhibitors in B-cell Lymphoid Neoplasms

28. Data from ERBB4-Mediated Signaling Is a Mediator of Resistance to PI3K and BTK Inhibitors in B-cell Lymphoid Neoplasms

29. Supplementary Table 6 from ERBB4-Mediated Signaling Is a Mediator of Resistance to PI3K and BTK Inhibitors in B-cell Lymphoid Neoplasms

30. IELSG38: phase II trial of front-line chlorambucil plus subcutaneous rituximab induction and maintenance in mucosa-associated lymphoid tissue lymphoma

31. Characterization of a novel humanized heavy chain antibody targeting endogenous retroviruses with anti-lymphoma activity

32. Proliferative History Is a Novel Driver of Clinical Outcome in Splenic Marginal Zone Lymphoma

34. Ibrutinib as first line therapy in chronic lymphocytic leukemia patients over 80 years old: A retrospective real‐life multicenter Italian cohort

35. A Heterogeneous RISC-V Based SoC for Secure Nano-UAV Navigation

36. Baseline circulating tumour DNA and interim PET predict response in relapsed/refractory classical Hodgkin lymphoma.

37. The VLA-4 integrin is constitutively active in circulating chronic lymphocytic leukemia cells via BCR autonomous signaling: a novel anchor-independent mechanism exploiting soluble blood-borne ligands

38. ERIC recommendations for TP53mutation analysis in chronic lymphocytic leukemia—2024 update

39. Marsellus: A Heterogeneous RISC-V AI-IoT End-Node SoC With 2–8 b DNN Acceleration and 30%-Boost Adaptive Body Biasing

40. Richter syndrome: pathogenesis and management

41. CD49d expression is included in a revised 4-factor model predicting outcome in patients with chronic lymphocytic leukemia treated with ibrutinib: A multicenter real-world experience.

42. ERBB4-Mediated Signaling Is a Mediator of Resistance to PI3K and BTK Inhibitors in B-cell Lymphoid Neoplasms.

Catalog

Books, media, physical & digital resources